Precision Brain Health Research Act of 2025

1) What happened and its current status: S. 800, the Precision Brain Health Research Act of 2025, was reported favorably out of the Senate Veterans' Affairs Committee on July 30, 2025. The bill is awaiting floor action. It expands the Scott Hannon Initiative for Precision Mental Health to include repetitive low-level blast exposure, dementia, and other brain conditions, and requires a VA-DoD data-sharing partnership. The bill is sponsored by Sen. Moran (R-KS), a senior committee member, with 3 cosponsors. It has not yet passed the Senate or House. 2) The money trail: This is an authorization-only bill — it expands the scope of an existing VA research program but does not appropriate any new funds. Authorization sets policy ceilings; actual spending requires a separate appropriations bill. Despite the committee advancement, no dollar amount is authorized in the bill text. Contract opportunities for diagnostic companies depend on future appropriations. The April 2026 executive order on mental health treatments signals administration interest in the broader space but does not directly fund this VA research program. 3) Structural winners and losers: The primary beneficiaries would be diagnostic testing service providers ($LH, $DGX) and potentially clinical research organizations ($IQV, $CRL) if the VA expands outsourced research services. However, without appropriation, these are speculative. IQVIA ($IQV) is down -9.26% in 7 days and -2.97% in 30 days; Charles River ($CRL) is down -9.75% in 7 days but up +4.79% in 30 days — both reflect broader sector trends, not legislative catalysts. 4) Analysis of real market data: $LH current at $259.57 (7-day -4.79%, 30-day -1.75%); $DGX at $195.05 (7-day -4.39%, 30-day -0.24%). Both show negative short-term momentum consistent with healthcare sector selling, with no breakout indicating legislative news catalysts. The 7-day declines for LH and DGX began around April 23, predating any new legislative developments. 5) Timeline: The bill must still pass the Senate floor, the House (no companion bill has been introduced), and be signed by the President. With the 119th Congress in its second session (2026), the window for passage narrows. Separately, an appropriations bill would need to fund any research expansion. This is a low-probability near-term catalyst.